<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:228003842;
mso-list-template-ids:-1531164234;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:910389829;
mso-list-template-ids:1007041772;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2
{mso-list-id:969671123;
mso-list-template-ids:942278064;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l2:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3
{mso-list-id:1553076591;
mso-list-template-ids:59828998;}
@list l3:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4
{mso-list-id:1819573078;
mso-list-template-ids:-1191045970;}
@list l4:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5
{mso-list-id:1978610527;
mso-list-template-ids:-309067260;}
@list l5:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.nsf.gov/pubs/2020/nsf20512/nsf20512.htm__;!!PhOWcWs!iwxBe6PLnmhouErjWD_0OHRAKKu5IoftUeVD__bV9Ao8t7Z9tpSjlR44BLAjYRhhQ7c5if0XEO-uXHHTVT8$" target="_blank">NSF: Understanding the Rules of Life: Epigenetics</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of the Understanding the Rules of Life: Epigenetics (URoL:Epigenetics) program is to enable innovative research and to promote multidisciplinary education and workforce training in the broad
area of epigenetics. The URoL:Epigenetics program is a wide collaboration across Directorates/Offices within the National Science Foundation with a focus on understanding the relationship between epigenetic mechanisms associated with environmental change,
organismal phenotype, and resultant robustness and adaptability of organisms and populations.
<i>Understanding the Rules of Life (URoL): Predicting Phenotype</i> is one of NSF’s 10 Big Ideas and is focused on predicting the set of observable characteristics (phenotype) from the genetic makeup of the individual and the nature of its environment. The
development of new research tools has revolutionized our ability to manipulate and investigate the genome and to measure multiple aspects of biological, physical, and social environments. The opportunity now is to assimilate this new information into causal,
mechanistic, and/or predictive relationships among the genomic and epigenetic makeup, the environmental experience, and the phenotypic characteristics of biological systems. These relationships are the basis for the Rules of Life – the theoretical constructs
that explain and predict the characteristics of living systems, from molecular and sub-cellular components, to cells, whole organisms, communities and biomes.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The recognition that heritable phenotypic properties can occur without modification of an organism’s genome sequence is changing the understanding of the way heritable traits come about and manifest themselves
as observable phenotypes within a particular static or changing environmental context. The impact of epigenetic inheritance occurs at the molecular, cellular, and organismal scales, and may have profound consequences for the higher-order organization of living
systems, including populations, communities, and ecosystems. Successful projects of the URoL:Epigenetics Program are expected to use complementary, interdisciplinary approaches to investigate how epigenetic phenomena lead to emergent properties that explain
the fundamental behavior of living systems. Ultimately, successful projects should identify general principles ("rules") that underlie biological phenomena within or across scales of size, complexity (e.g., molecular, cellular, organismal, population) and
time (from sub-second to geologic) in taxa from anywhere within the tree of life, including humans.
<b>URoL:Epigenetics projects must integrate perspectives and research approaches from more than one research discipline (e.g., biology, chemistry, computer science, engineering, geology, mathematics, physics, social and behavioral sciences).
</b>The interdisciplinary scope of URoL:Epigenetics projects also provides unique training and outreach possibilities to train the next generation of scientists in a diversity of approaches and to engage society more generally. The URoL:Epigenetics Program
offers two submission tracks: Track 1 - for projects with a total budget of up to $500,000 and an award duration of up to 3 years, and Track 2 - for projects with a total budget of up to $3,000,000 and award duration of up to 5 years.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Required letter of intent due December 20, 2019; proposal due February 6, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: December 9, 2019 / January 27, 2020.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://pardeefoundation.org/how-to-apply/__;!!PhOWcWs!iwxBe6PLnmhouErjWD_0OHRAKKu5IoftUeVD__bV9Ao8t7Z9tpSjlR44BLAjYRhhQ7c5if0XEO-uqcUP61U$" target="_blank">Elsa U. Pardee Foundation: Cancer Research Grants</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Elsa U. Pardee Foundation funds research to investigators in United States non-profit institutions proposing research directed toward identifying new treatments or cures for cancer. The Foundation
particularly encourages grant applications for a one year period which will allow establishment of capabilities of new cancer researchers, or new cancer approaches by established cancer researchers. It is anticipated that this early stage funding by the Foundation
may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified. By design, there are no limits set on the grant amount that can be requested. It must be reasonably
and clearly supported by the scope of the project outlined in the application.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due December 31, 2019, April 30, 2020, August 31, 2020.
<span style="color:red">Med-RA deadline to receive draft documents for December 31 deadline: December 9, 2019 (accounting for holiday closure.)</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://parkinsonsroadmap.org/work-with-us/__;!!PhOWcWs!iwxBe6PLnmhouErjWD_0OHRAKKu5IoftUeVD__bV9Ao8t7Z9tpSjlR44BLAjYRhhQ7c5if0XEO-umVuFG7A$" target="_blank">Aligning Science Across Parkinson’s: Collaborative Research Network</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Aligning Science Across Parkinson’s (ASAP) requests applications from multidisciplinary research teams interested in forming and participating in the ASAP Collaborative Research Network. Through the network,
ASAP seeks to fund research projects that address key knowledge gaps in the basic mechanisms that contribute to Parkinson’s development and progression. Proposals must focus on one of the following scientific themes: biology of PD-associated genetics, and
neuro-immune interactions.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Through the RFA, up to $9 million over three years will be awarded to teams selected to participate in the network. Applications must be submitted by multidisciplinary, multi-institutional research teams
consisting of three to five investigators. Teams may be from the U.S. or international in nature, and can include public and private nonprofit groups, agencies of the U.S. federal government, and for-profit entities.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Pre-proposals due January 8, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: January 2, 2020.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.dkms.org/en/john-hansen-grant__;!!PhOWcWs!iwxBe6PLnmhouErjWD_0OHRAKKu5IoftUeVD__bV9Ao8t7Z9tpSjlR44BLAjYRhhQ7c5if0XEO-uOC59rY8$" target="_blank">DKMS Foundation: John Hansen Research Grant -- Study of Hematopoietic Stem Cell Transplantation and Cell Therapies in Hematologic Malignancies</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.dkms.org/en__;!!PhOWcWs!iwxBe6PLnmhouErjWD_0OHRAKKu5IoftUeVD__bV9Ao8t7Z9tpSjlR44BLAjYRhhQ7c5if0XEO-u6o1ezBg$" target="_self">DKMS</a>, the world’s largest bone marrow donor center, invites young researchers to apply for one of the four scholarships awarded by the DKMS Foundation
for Giving Life through its John Hansen Research Grant program. Each of the four recipients of a Hansen grant will receive approximately $266,000 over a period of three years. The research should be in the field of stem cell therapy and have the goal of sustainably
and effectively supporting and advancing the fight against blood cancer. Various aspects may be covered, including but not restricted to transplant immunology, stem cell donation, cell manufacturing, as well as diagnostic and therapeutic strategies.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Applicants must have a doctoral degree that was awarded within the past eight years. <o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due January 8, 2020. <span style="color:red">
Med-RA deadline to receive draft documents: January 2, 2020.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Research/National_MS_Society_EMD_RfA_2019.pdf__;!!PhOWcWs!iwxBe6PLnmhouErjWD_0OHRAKKu5IoftUeVD__bV9Ao8t7Z9tpSjlR44BLAjYRhhQ7c5if0XEO-uN-E3SHc$" target="_blank">Multiple Sclerosis Society: Pilot Research on Effects of
Aging on MS</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Through this RFA, the organization seeks to advance understanding of how aging contributes to the pathogenesis and natural history of MS progression and to use that knowledge to reveal potential targets
and develop strategies that slow down or stop disability progression. To that end, grants of up to $50,000 will be awarded to innovative, cutting-edge ideas or untested methods aimed at understanding the impact of aging on MS and to gather enough preliminary
data to apply for longer-term funding. Areas of focus for this program include but are not limited to approaches directed at removing barriers to OPC maturation so as to improve remyelination and/or neuroprotection (including stimulation of endogenous repair
and cell-based approaches); therapeutic regulation of senescence to enhance regenerative capacity of neural progenitor cells; determining the impact of senescence on microglial/macrophage functions such as clearance of myelin debris; evaluating T and B cell
senescence and its contribution to the transition of MS from an inflammatory to a neurodegenerative condition; assessing astrocyte-endothelial integrity and maintenance of the blood-brain barrier; determining the contribution of senescent neurons/glial cells
to neurodegenerative processes that lead to brain atrophy and disability progression; and understanding mechanisms whereby juvenile MS patients experience secondary progressive MS sooner than adult patients.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Pre-applications due January 8, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: January 2, 2020.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://jlabs.jnjinnovation.com/quickfire-challenges/diversity-innovation-quickfire-challenge__;!!PhOWcWs!iwxBe6PLnmhouErjWD_0OHRAKKu5IoftUeVD__bV9Ao8t7Z9tpSjlR44BLAjYRhhQ7c5if0XEO-uVLeEiLo$" target="_blank">Johnson & Johnson: Diversity in Innovation QuickFire Challenge Grants</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Johnson & Johnson invites applications for its Diversity in Innovation QuickFire Challenge. Through the program, grants of up to $250,000 will be awarded to multicultural innovator(s), including black/
African American, Hispanic/ Latino, and American Indian or Alaska Native, with the best idea, technology, or solution aimed at improving human healthcare. In addition to funding, awardees will be given access to the global JLABS network and mentorship from
experts at the Johnson & Johnson Family of Companies. While innovations in all aspects of healthcare are encouraged, J&J is particularly interested in the pharmaceutical, consumer healthcare, health technology, medical device, and cross-sectoral initiatives.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due January 9, 2020. <span style="color:red">
Med-RA deadline to receive draft documents: January 2, 2020.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__http://wtgrantfoundation.org/grants__;!!PhOWcWs!iwxBe6PLnmhouErjWD_0OHRAKKu5IoftUeVD__bV9Ao8t7Z9tpSjlR44BLAjYRhhQ7c5if0XEO-ukBci4UA$">William T. Grant Foundation: Research Grants</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">We fund research that increases understanding in one of our two focus areas:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l0 level1 lfo3"><span style="font-family:Palatino">programs, policies, and practices that
<a href="https://urldefense.com/v3/__http://wtgrantfoundation.org/focus-areas/reducing-inequality__;!!PhOWcWs!iwxBe6PLnmhouErjWD_0OHRAKKu5IoftUeVD__bV9Ao8t7Z9tpSjlR44BLAjYRhhQ7c5if0XEO-u3mbRUxI$">reduce inequality</a> in youth outcomes, and<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo3"><span style="font-family:Palatino">strategies to
<a href="https://urldefense.com/v3/__http://wtgrantfoundation.org/focus-areas/improving-use-research-evidence__;!!PhOWcWs!iwxBe6PLnmhouErjWD_0OHRAKKu5IoftUeVD__bV9Ao8t7Z9tpSjlR44BLAjYRhhQ7c5if0XEO-uuZne4kM$">
improve the use of research evidence</a> in ways that benefit youth.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-family:Palatino">The <b>Reducing Inequality program</b> supports high-quality field-initiated studies from a range of disciplines and methodologies that are relevant to policies and practices that affect the lives of young
people between the ages of 5 and 25 in the United States. Through the program, grants of up to $600,000 over a period of up to three years will be awarded in support of major research designed to build, test, or increase understanding of programs, policies,
or practices with the potential to reduce inequality in the academic, social, behavioral, or economic outcomes of young people. Descriptive studies that clarify mechanisms for reducing inequality or elucidate how or why a specific program, policy, or practice
operates to reduce inequality are welcomed.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The foundation prioritizes studies about reducing inequality on the basis of race, ethnicity, economic standing, language, minority status, or immigrant origin. It also welcomes studies from a range of
disciplines, fields, and methodologies and encourages investigations into various systems, including justice, housing, child welfare, mental health, and education. Competitive proposals often incorporate data from multiple sources and often involve multidisciplinary
teams. In addition to financial support, grantees receive significant time and capacity-building resources from the foundation. Projects led by African American, Latinx, Native American, and Asian Pacific American researchers are encouraged.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"> The <b>Improving the Use of Research Evidence program</b> supports high-quality field-initiated studies that identify, build, and test strategies to enhance the use of research evidence in
ways that benefit youth (ages 5 to 25 in the US). We are particularly interested in research on improving the use of research evidence by state and local decision makers, mid-level managers, and intermediaries. Some investigators will focus on the strategies,
relationships, and other supports needed for policy and practice organizations to use research more routinely and constructively. Others may investigate structures and incentives within the research community to encourage deep engagement with decision makers.
Still other researchers may examine activities that help findings inform policy ideas, shape practice responses, and improve systems.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Letters of inquiry to either program due January 9, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: January 2, 2020.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.sfari.org/grant/research-awards-request-for-applications/__;!!PhOWcWs!iwxBe6PLnmhouErjWD_0OHRAKKu5IoftUeVD__bV9Ao8t7Z9tpSjlR44BLAjYRhhQ7c5if0XEO-urJGeJmE$" target="_blank">Simons Foundation Autism Research Initiative (SFARI): Research Award</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Grants awarded through this RFA are intended to provide support for the investigation of key unresolved research questions in autism, particularly those that connect etiology to brain function and behavior.
SFARI welcomes risk and novelty in Research Award proposals, but potential impact on the autism research field will be the most important criterion. Competitive applications will have preliminary data or other relevant groundwork that justifies substantial
investment on the proposed topic.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The maximum budget is $1,300,000, including indirect costs, over a period of up to four years.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due January 10, 2020. <span style="color:red">
Med-RA deadline to receive draft documents: January 2, 2020.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.nsf.gov/pubs/2020/nsf20513/nsf20513.htm?WT.mc_id=USNSF_25&WT.mc_ev=click__;!!PhOWcWs!iwxBe6PLnmhouErjWD_0OHRAKKu5IoftUeVD__bV9Ao8t7Z9tpSjlR44BLAjYRhhQ7c5if0XEO-u4xYgZKU$" target="_blank">Understanding the Rules of Life: Microbiome Theory and Mechanisms (URoL:MTM)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Understanding the Rules of Life (URoL): Predicting Phenotype is one of NSF's 10 big ideas (<a href="https://urldefense.com/v3/__https://www.nsf.gov/news/special_reports/big_ideas/__;!!PhOWcWs!iwxBe6PLnmhouErjWD_0OHRAKKu5IoftUeVD__bV9Ao8t7Z9tpSjlR44BLAjYRhhQ7c5if0XEO-uuYEiqfg$">https://www.nsf.gov/news/special_reports/big_ideas/</a>)
and is focused on predicting the set of observable characteristics (phenotypes) based on the genetic makeup of the individual and the nature of its environment. The Understanding the Rules of Life: Microbiome Theory and Mechanisms (URoL:MTM) program is an
integrative collaboration across Directorates and Offices within the National Science Foundation. The objective of URoL:MTM is to understand and establish the theory and mechanisms that govern the structure and function of microbiomes, a collection of microbes
in a specific habitat/environment. This may include but is not limited to host-associated microbiomes, such as those with humans and other organisms, where i) the microbiome impacts host physiology, behavior, development, and fitness; ii) the host influences
the metabolic activity, dynamics and evolution of the microbiome, and iii) the environment (biological, chemical, physical, and social) influences and is influenced by both the host and the microbiome. Recent progress has transformed our ability to identify
and catalogue the microbes present in a given environment and measure multiple aspects of biological, chemical, physical, and social environments that affect the interactions among the members of the microbiome, the host, and/or habitat. Much descriptive and
correlative work has been performed on many microbiome systems, particularly those in the human, soil, aquatic, and built environments. This research has resulted in new hypotheses about the microbiome's contributions to potential system function or dysfunction.
The current challenge is to integrate the wide range of accumulated data and information and build on them to develop new causal/mechanistic models or theories of interactions and interdependencies across scales and systems. Elucidating these relationships
informs our understanding of the Rules of Life – the theoretical constructs and models that explain and predict the characteristics of living systems, spanning from molecular and sub-cellular components, to cells, whole organisms, communities, and biomes.<o:p></o:p></span></p>
<p class="MsoNormal" style="text-indent:.5in"><span style="font-family:Palatino">The URoL:MTM program invites integrated, interdisciplinary proposals that develop theoretical predictive frameworks with well-designed experimental and/or computational approaches
to generate and test hypotheses about the causal relationships within the microbiome, and among the microbiome, host, and environment. How these relationships affect robustness, resilience, and adaptability of individual organisms, populations, and communities
are also of interest. Projects may apply existing ecological and evolutionary theory or develop new experimental, computational, or mathematical tools, models, and theory to: i) explain function and interactions in natural, experimental, and model microbiomes;
ii) elucidate the molecular mechanisms that underlie communication between the host and the microbiome and among the members of the microbiome; and/or iii) comparatively analyze microbiomes to discover emergent properties that provide insight into the behavior
of living systems.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Successful projects will contribute to a portfolio of research that identifies general principles ("rules") that underlie a wide spectrum of biological phenomena across spatial, temporal (from sub-second
to geologic), and/or complexity (molecular, cellular, organismal, population) scales. URoL:MTM projects must integrate perspectives and research approaches from more than one research discipline (e.g., biology, chemistry, computer science, engineering, geosciences,
mathematics, physics, social and behavioral sciences). They must also incorporate best practices regarding protocol documentation, sample selection, data collection and analysis, model/algorithm development, as well as data sharing and accessibility. The interdisciplinary
scope of URoL:MTM projects should provide unique training and outreach opportunities to train the next generation of scientists in a diversity of scientific approaches and to engage society more generally. URoL:MTM supports basic science research projects
of different scales and scope.<o:p></o:p></span></p>
<p class="MsoNormal" style="text-indent:.5in"><span style="font-family:Palatino">The URoL:MTM Program offers two submission tracks: Track 1 for projects with a total budget of up to $500,000 and an award duration of up to 3 years and Track 2 for projects with
a total budget of up to $3,000,000 and award duration of up to 5 years.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Required letter of intent due January 17, 2020; proposals due March 2, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: January 6 / February 18, 2020.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://professional.heart.org/professional/ResearchPrograms/UCM_497208_Transformational-Project-Award.jsp__;!!PhOWcWs!iwxBe6PLnmhouErjWD_0OHRAKKu5IoftUeVD__bV9Ao8t7Z9tpSjlR44BLAjYRhhQ7c5if0XEO-uhOeDqPs$" target="_blank">American Heart Association: Transformational Project Award</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Purpose<o:p></o:p></span></b></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l2 level1 lfo6"><span style="font-family:Palatino">To support highly innovative, high-impact projects that build on work in progress that could ultimately lead to critical discoveries or major advancements that will accelerate
the field of cardiovascular and/or cerebrovascular research.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo6"><span style="font-family:Palatino">Research deemed innovative may be built around an emerging paradigm, approaching an existing problem from a new perspective, or exhibit other uniquely creative qualities.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo6"><span style="font-family:Palatino">Successful applications are likely to be those building on strong preliminary data supportive of the hypothesis.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo6"><span style="font-family:Palatino">This program aims to provide funding that should lead to successful competition for additional funding beyond the award period. The principal investigator (PI) is responsible
for clearly and explicitly articulating the project’s innovation and the potential impact on cardiovascular and/or cerebrovascular research.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-family:Palatino">Science Focus<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino">The AHA funds basic, clinical, behavioral, translational and population research, bioengineering/biotechnology and public health problems broadly related to fulfilling our mission to be a relentless force
for a world of longer, healthier lives.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Annual Award Amount:</span></b><span style="font-family:Palatino"> $100,000, including 10% IDC.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Award Duration:</span></b><span style="font-family:Palatino"> Three years.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Total Award Amount:</span></b><span style="font-family:Palatino"> $300,000<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due January 22, 2020. <span style="color:red">
Med-RA deadline to receive draft documents: January 13, 2020.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://habri.org/funding-opportunities__;!!PhOWcWs!iwxBe6PLnmhouErjWD_0OHRAKKu5IoftUeVD__bV9Ao8t7Z9tpSjlR44BLAjYRhhQ7c5if0XEO-uf63P7bg$" target="_blank">Human Animal Bond Research Institute (HABRI): Addressing Evidence-Based Health Benefits of Human-Animal Interaction</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The vision of the HABRI is for the human-animal bond to be universally embraced as an essential element of human wellness. To that end, HABRI works to establish the vital role of companion animals in the
health and well-being of individuals, families and communities. HABRI is calling for research proposals to investigate the health outcomes of pet ownership and/or animal-assisted activity or therapy, both for the people and the animals involved. Proposals
should have a strong theoretical framework and focus on innovative approaches to studying the health effects of companion animals on humans within the following broad categories:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l1 level1 lfo9"><span style="font-family:Palatino">Child Health and Development<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo9"><span style="font-family:Palatino">Healthy Aging<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo9"><span style="font-family:Palatino">Mental & Physical Health and Wellness<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-family:Palatino">In an effort to help address larger societal challenges, proposals that have potential to impact current public health crises or issues at the forefront of public concern are welcomed. Topics include (but
are not limited to) social isolation and loneliness, suicide prevention, addiction, trauma and/or post-traumatic stress, obesity and heart health.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due February 13, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: February 3, 2020.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span></b><span style="font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b><span style="color:red">CoM’s
unofficial funding opportunities blog</span></b></a></span><b><span style="font-family:Palatino;color:red">.</span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
</div>
</body>
</html>